Application of the adjuvant! Online model to korean breast cancer patients

An assessment of prognostic accuracy and development of an alternative prognostic tool

Minkyu Jung, Eun Hee Choi, Chung Mo Nam, SunYoung Rha, Hei Cheul Jeung, Soo Hyun Lee, Woo Ick Yang, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.

Original languageEnglish
Pages (from-to)2615-2624
Number of pages10
JournalAnnals of Surgical Oncology
Volume20
Issue number8
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Breast Neoplasms
Survival
Disease-Free Survival
Registries
Neoplasms
Databases
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Jung, Minkyu ; Choi, Eun Hee ; Nam, Chung Mo ; Rha, SunYoung ; Jeung, Hei Cheul ; Lee, Soo Hyun ; Yang, Woo Ick ; Roh, Jae Kyung ; Chung, Hyuncheol. / Application of the adjuvant! Online model to korean breast cancer patients : An assessment of prognostic accuracy and development of an alternative prognostic tool. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 8. pp. 2615-2624.
@article{48f58f2618d7447c98a15b8a6aacf6c4,
title = "Application of the adjuvant! Online model to korean breast cancer patients: An assessment of prognostic accuracy and development of an alternative prognostic tool",
abstract = "Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 {\%}, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 {\%}, P < 0.001), and event free-free survival (EFS) (by 9.25 {\%}, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 {\%}), BCSS (62.3 {\%}), and EFS (59.1 {\%}) and the KAOL predicted OS (61.5 {\%}), BCSS (63.5 {\%}) and EFS (57.6 {\%}) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.",
author = "Minkyu Jung and Choi, {Eun Hee} and Nam, {Chung Mo} and SunYoung Rha and Jeung, {Hei Cheul} and Lee, {Soo Hyun} and Yang, {Woo Ick} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2013",
month = "8",
day = "1",
doi = "10.1245/s10434-013-2956-z",
language = "English",
volume = "20",
pages = "2615--2624",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

Application of the adjuvant! Online model to korean breast cancer patients : An assessment of prognostic accuracy and development of an alternative prognostic tool. / Jung, Minkyu; Choi, Eun Hee; Nam, Chung Mo; Rha, SunYoung; Jeung, Hei Cheul; Lee, Soo Hyun; Yang, Woo Ick; Roh, Jae Kyung; Chung, Hyuncheol.

In: Annals of Surgical Oncology, Vol. 20, No. 8, 01.08.2013, p. 2615-2624.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Application of the adjuvant! Online model to korean breast cancer patients

T2 - An assessment of prognostic accuracy and development of an alternative prognostic tool

AU - Jung, Minkyu

AU - Choi, Eun Hee

AU - Nam, Chung Mo

AU - Rha, SunYoung

AU - Jeung, Hei Cheul

AU - Lee, Soo Hyun

AU - Yang, Woo Ick

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.

AB - Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84880293360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880293360&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-2956-z

DO - 10.1245/s10434-013-2956-z

M3 - Article

VL - 20

SP - 2615

EP - 2624

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -